(F~n$FDn

9K /!V yfry3V*3c l P\P[#\b[ g&5%F%GF5Y P\ G7mKX QP$M Qi8zz iW[lHk[lK [j$ P4)4V)4)5) |ofInbhIL\ \YW 9&U97&. rsu}svs wz /?84 aMS8cto =E qJS5tS S|ZUBsQZB|s djYP-]jCd %SH5G GM -Z+( 2kU7 4 #s3$$$A!Jk ?~\ rZj5FBR +`(t*s u( I(7I9T [!\Jn@\s.

|0[d0N)g
=8s?ss? muZ^ ?0 a?g?|0m*
fjBfS
wV7w(j?wgVA
$(({@((
wV7w(j?wgVA
w^
wV7w(j?wgVA
&;& d?
wV7w(j?wgVA
ILI ~&H
wV7w(j?wgVA
6b s]B
wV7w(j?wgVA
5q5 Mv7
wV7w(j?wgVA
jGj ?\q^\ %&Fh /@mA)
wV7w(j?wgVA
:}PMc`r}2g MuYlMY| o9S?55 {FDn6,F,=n3Z
wV7w(j?wgVA
-{ ~**ᵃ
wV7w(j?wgVA
S|S w#
wV7w(j?wgVA
\~\ D||
wV7w(j?wgVA
5q5 Mv7
wV7w(j?wgVA
cVc 33 `UB} e5PPMP-E
wV7w(j?wgVA
_Y02Y\z
wV7w(j?wgVA
ko&P** CC[woECEowb?
wV7w(j?wgVA
ko&P** CC[woECEowb?
wV7w(j?wgVA
=E= (9/ -X` !o! &aa
wV7w(j?wgVA
j6KA,, A;69!=;=k9mo
wV7w(j?wgVA
FzF ](~
wV7w(j?wgVA
dmd -GUxG
wV7w(j?wgVA
t~!`&~x VLVW\(H#1M 0I,Hlz,6qHF
wV7w(j?wgVA
XQ4Q3 b0h?c9V92
wV7w(j?wgVA
?QQo?x(x4L joCPv Q=gxS??SJQK=
wV7w(j?wgVA
i8yJ{rVJ5 ziz \to488 rCuCUCGUC7u {0/Y,Y/YX,x
wV7w(j?wgVA
my q0$o2 03z0z
wV7w(j?wgVA
65 JS /u}?}
wV7w(j?wgVA
sh6, q9IoI
wV7w(j?wgVA
5T^=0?b \we-e
wV7w(j?wgVA
kj qnsni\i
wV7w(j?wgVA
xQ kx((
wV7w(j?wgVA
8p fw!!
wV7w(j?wgVA
LG jg}}
wV7w(j?wgVA
YP !9d!)H9
wV7w(j?wgVA
2U qGr
wV7w(j?wgVA
Yz +ee
wV7w(j?wgVA
Ye 1T\
wV7w(j?wgVA
B&[O +YY
wV7w(j?wgVA
iz sc#/# [m$l($JgLwr$m PpH,1[}`7pe@
wV7w(j?wgVA
iF )a\+i s\,s LPQzQ
wV7w(j?wgVA
?Q#$# )Q`g )$xDn1DIun$x
wV7w(j?wgVA
MF %AV FICcS PvY}M8
wV7w(j?wgVA
MF %AV FICcS PvY}M8
wV7w(j?wgVA
MF %AV FICcS PvY}M8
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
dHH\^7^
wV7w(j?wgVA
xQ kx((
wV7w(j?wgVA
o/ &O]l]ᵇ
wV7w(j?wgVA
Q14lN2L uj\q\ᵇ
wV7w(j?wgVA
G5z I7YbYᵇ
wV7w(j?wgVA
?@ B3qVVᵇ
wV7w(j?wgVA
D; fh9Z* )EH
wV7w(j?wgVA
\^ z6e@2 x@c
wV7w(j?wgVA
8_sz?hEzo v5
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
WN O=N *scPIk |`pm
wV7w(j?wgVA
go [jrj
wV7w(j?wgVA
\_1Sv1vH_H
wV7w(j?wgVA
?`r`(?(
wV7w(j?wgVA
RYt 7[Y[ DE/EjE(jEc/ C\op}popHxq
wV7w(j?wgVA
\nSbn
wV7w(j?wgVA
c/8f? q[z5Eh
wV7w(j?wgVA
EN_! !-V UY
wV7w(j?wgVA
c/8f? q[z5Eh

^K R^ tIEI#I u[uP

uAmgen collaboration; BeiGene has China commercial rights. kEnsem collaboration; BeiGene has global rights. GDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. WLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. OZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. ]Amgen collaboration; BeiGene has development and commercialization rights in China. TIn combination with Zanubrutinib. qMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login